Insiders Trades

★ Sign in to follow

EM

Edward Miller

Directeur Juridique

US·SEC (Form 4)

Allovir, Inc.Alexion Pharmaceuticals Inc

Insider activity · 24 months0 buys5 salesCumulative net flow

Nov 24 · 0 buys · 2 salesDec 24 · 0 buys · 0 salesJan 25 · 0 buys · 2 salesFeb 25 · 0 buys · 1 saleMar 25 · 0 buys · 0 salesApr 25 · 0 buys · 0 salesMay 25 · 0 buys · 0 salesJun 25 · 0 buys · 0 salesJul 25 · 0 buys · 0 salesAug 25 · 0 buys · 0 salesSept 25 · 0 buys · 0 salesOct 25 · 0 buys · 0 salesNov 25 · 0 buys · 0 salesDec 25 · 0 buys · 0 salesJan 26 · 0 buys · 0 salesFeb 26 · 0 buys · 0 salesMar 26 · 0 buys · 0 salesApr 26 · 0 buys · 0 salesMay 26 · 0 buys · 0 salesJun 26 · 0 buys · 0 salesJul 26 · 0 buys · 0 salesAug 26 · 0 buys · 0 salesSept 26 · 0 buys · 0 salesOct 26 · 0 buys · 0 sales

Total declarations

59

Companies

2

▲ Purchases (0 ops.)

—

▼ Sales (42 ops.)

€725k

Latest filing published 24 Feb 2025 for Allovir, Inc., €1,017.

Filing timeline

BuySale

Edward Miller

Insider track record

Disclosed buys

0

Disclosed sells

42

Not enough buy signals with a settled T+90 horizon to measure a track record yet.

Signal history

Edward Miller: trading record in brief

Edward Miller is a declared insider at 2 companies (senior executive); the most frequent names are Kalaris Therapeutics, Inc. and Alexion Pharmaceuticals Inc. Over a trading history stretching from 8 September 2014 to 21 February 2025, the count stands at 59 filings.

Sales make up the whole of the open-market record (42 sales, €725k). Besides market trades, the filings include 10 share grants. 2025 to date brings no purchases and 4 sales.

On 24 February 2025 came the latest disclosure, an open-market sale for €1,017 in Kalaris Therapeutics, Inc. Filings reach the SEC (Form 4) feed a median of 3 days after the trade. The legal deadline for a Form 4 is two business days after the transaction. Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.

Companies and markets linked to Edward Miller

Open company profiles for insider transactions, fundamentals and analyst consensus when available.

Allovir, Inc. (US)Alexion Pharmaceuticals Inc (US)

Declarations36 total

▼

General CounselExecutives21 Feb 2025Allovir, Inc.

1,068 USD26SEC

106 shares@ US$10.07582.1% of flowCommon StockSEC:0000950170-25-025630:0

▼

General CounselExecutives23 Jan 2025Allovir, Inc.

444 USD26SEC

47 shares@ US$9.45380.9% of flowCommon StockSEC:0000950170-25-009205:0

▼

General CounselExecutives10 Jan 2025Allovir, Inc.

180 USD26SEC

409 shares@ US$0.44010.4% of flowCommon StockSEC:0000950170-25-004834:0

●

General CounselExecutives11 Dec 2024Allovir, Inc.

0SEC

57,549 shares0Common StockSEC:0000950170-24-135443:0

▼

General CounselExecutives19 Nov 2024Allovir, Inc.

237 USD29SEC

432 shares@ US$0.54850.5% of flowCommon StockSEC:0000950170-24-129258:0

▼

General CounselExecutives5 Nov 2024Allovir, Inc.

1,965 USD29SEC

2,272 shares@ US$0.86493.7% of flowCommon StockSEC:0000950170-24-122335:0

▼

General CounselExecutives21 Oct 2024Allovir, Inc.

495 USD29SEC

635 shares@ US$0.7790.9% of flowCommon StockSEC:0000950170-24-116644:0

▼

General CounselExecutives3 Oct 2024Allovir, Inc.

307 USD29SEC

377 shares@ US$0.81480.6% of flowCommon StockSEC:0000950170-24-112913:0

▼

General CounselExecutives19 Aug 2024Allovir, Inc.

321 USD29SEC

422 shares@ US$0.75950.6% of flowCommon StockSEC:0000950170-24-099106:0

▼

General CounselExecutives5 Aug 2024Allovir, Inc.

1,707 USD29SEC

2,323 shares@ US$0.73483.2% of flowCommon StockSEC:0000950170-24-092808:0

▼

General CounselExecutives19 Jul 2024Allovir, Inc.

476 USD29SEC

634 shares@ US$0.75010.9% of flowCommon StockSEC:0000950170-24-085658:0

▼

General CounselExecutives22 Jul 2024Allovir, Inc.

560 USD29SEC

757 shares@ US$0.73921.1% of flowCommon StockSEC:0000950170-24-085658:1

▼

General CounselExecutives2 Jul 2024Allovir, Inc.

273 USD29SEC

379 shares@ US$0.720.5% of flowCommon StockSEC:0000950170-24-081519:0

▼

General CounselExecutives17 May 2024Allovir, Inc.

315 USD29SEC

420 shares@ US$0.74930.6% of flowCommon StockSEC:0000950170-24-062977:0

▼

General CounselExecutives3 May 2024Allovir, Inc.

1,840 USD29SEC

2,311 shares@ US$0.7963.5% of flowCommon StockSEC:0000950170-24-054509:0

▼

General CounselExecutives19 Apr 2024Allovir, Inc.

470 USD29SEC

626 shares@ US$0.75060.9% of flowCommon StockSEC:0000950170-24-046907:0

▼

General CounselExecutives22 Apr 2024Allovir, Inc.

568 USD29SEC

757 shares@ US$0.751.1% of flowCommon StockSEC:0000950170-24-046907:1

▼

General CounselExecutives2 Apr 2024Allovir, Inc.

284 USD29SEC

368 shares@ US$0.7720.5% of flowCommon StockSEC:0000950170-24-041809:0

▼

General CounselExecutives20 Feb 2024Allovir, Inc.

268 USD29SEC

385 shares@ US$0.69520.5% of flowCommon StockSEC:0000950170-24-018786:0

▼

General CounselExecutives5 Feb 2024Allovir, Inc.

5,942 USD30SEC

8,869 shares@ US$0.6711.4% of flowCommon StockSEC:0000950170-24-011771:0

▼

General CounselExecutives23 Jan 2024Allovir, Inc.

873 USD29SEC

1,302 shares@ US$0.67081.7% of flowCommon StockSEC:0000950170-24-007403:0

▼

General CounselExecutives4 Jan 2024Allovir, Inc.

271 USD29SEC

424 shares@ US$0.6390.5% of flowCommon StockSEC:0000950170-24-002937:0

◆

General CounselExecutives2 Feb 2023Allovir, Inc.

0SEC

87,500 shares0Common StockSEC:0001209191-23-006992:0

●

General CounselExecutives2 Dec 2022Allovir, Inc.

0SEC

98,346 shares0Common StockSEC:0001209191-23-004501:0

▼

General CounselExecutives14 Nov 2022Allovir, Inc.

21,018 USD33SEC

2,358 shares@ US$8.913542.0% of flowCommon StockSEC:0000899243-22-036018:0

25 of 36 declarations